ChengDu ShengNuo Biotec Co.,Ltd.

SHSE:688117 Stock Report

Market Cap: CN¥3.0b

ChengDu ShengNuo BiotecLtd Balance Sheet Health

Financial Health criteria checks 5/6

ChengDu ShengNuo BiotecLtd has a total shareholder equity of CN¥918.7M and total debt of CN¥398.9M, which brings its debt-to-equity ratio to 43.4%. Its total assets and total liabilities are CN¥1.5B and CN¥609.4M respectively. ChengDu ShengNuo BiotecLtd's EBIT is CN¥105.0M making its interest coverage ratio 13.7. It has cash and short-term investments of CN¥230.6M.

Key information

43.4%

Debt to equity ratio

CN¥398.93m

Debt

Interest coverage ratio13.7x
CashCN¥230.62m
EquityCN¥918.65m
Total liabilitiesCN¥609.40m
Total assetsCN¥1.53b

Recent financial health updates

No updates

Recent updates

ChengDu ShengNuo BiotecLtd (SHSE:688117) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 04
ChengDu ShengNuo BiotecLtd (SHSE:688117) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

ChengDu ShengNuo Biotec Co.,Ltd. (SHSE:688117) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable

Aug 26
ChengDu ShengNuo Biotec Co.,Ltd. (SHSE:688117) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable

A Look At The Fair Value Of ChengDu ShengNuo Biotec Co.,Ltd. (SHSE:688117)

Jun 19
A Look At The Fair Value Of ChengDu ShengNuo Biotec Co.,Ltd. (SHSE:688117)

ChengDu ShengNuo BiotecLtd (SHSE:688117) Strong Profits May Be Masking Some Underlying Issues

Apr 29
ChengDu ShengNuo BiotecLtd (SHSE:688117) Strong Profits May Be Masking Some Underlying Issues

There's Reason For Concern Over ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) Massive 27% Price Jump

Mar 04
There's Reason For Concern Over ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) Massive 27% Price Jump

Financial Position Analysis

Short Term Liabilities: 688117's short term assets (CN¥651.4M) exceed its short term liabilities (CN¥467.4M).

Long Term Liabilities: 688117's short term assets (CN¥651.4M) exceed its long term liabilities (CN¥142.0M).


Debt to Equity History and Analysis

Debt Level: 688117's net debt to equity ratio (18.3%) is considered satisfactory.

Reducing Debt: 688117's debt to equity ratio has increased from 0.4% to 43.4% over the past 5 years.

Debt Coverage: 688117's debt is well covered by operating cash flow (20.2%).

Interest Coverage: 688117's interest payments on its debt are well covered by EBIT (13.7x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:22
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ChengDu ShengNuo Biotec Co.,Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai WangCitic Securities Co., Ltd.